Company Profile

Vitro Diagnostics, Inc., doing business as Vitro Biopharma, is engaged in the development, manufacturing and distribution of stem cell products and related tools for use in research, drug discovery and clinical trials. The Company's clinical products include clinical grade MSC-Gro for mesenchymal stem cell (MSC) expansion prior to transplantation; an equine MSC cell line with application to treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, and others; testing and therapies related to endogenous stem cell activation; diagnostic testing of stem cell activation and determination of stem cell functional status, and cell-based assays for discovery of stem cell activation agents and new drugs for the treatment of osteoporosis. The Company offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells.

Employees

Sector

Pharmaceuticals

More about the company

03-16	Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2026	CI
02-13	Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2025	CI
25-09-12	Vitro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2025	CI
25-06-20	Vitro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2025	CI
25-05-26	Vitro Biopharma, Inc. announced a financing transaction	CI
25-03-20	Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2025	CI
25-01-28	Vitro Biopharma, Inc. Reports Earnings Results for the Full Year Ended October 31, 2024	CI
25-01-27	Vitro Biopharma, Inc. Auditor Raises 'Going Concern' Doubt	CI
24-09-16	Vitro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2024	CI
24-05-31	Vitro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024	CI
24-05-12	Vitro Biopharma, Inc. announced that it has received $0.3 million in funding	CI
24-04-10	Vitro Biopharma, Inc. announced that it has received $0.175 million in funding	CI
24-03-14	Vitro Biopharma, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	CI

20-10-05	VITRO DIAGNOSTICS INC : Regulation FD Disclosure (form 8-K)	AQ
20-10-05	VITRO DIAGNOSTICS INC : Other Events (form 8-K)	AQ
20-07-14	Vitro Diagnostics : Biopharma 2nd Quarter ended April 30th 2020 Financial Results of Operations	AQ
20-07-09	VITRO DIAGNOSTICS INC : Regulation FD Disclosure (form 8-K)	AQ
20-06-04	VITRO DIAGNOSTICS INC : Entry into a Material Definitive Agreement, Regulation FD Disclosure (form 8-K)	AQ

Manager	Title	Age	Since
Christopher Furman CEO	Chief Executive Officer	55	2022-06-30
James Musick CEO	Chief Executive Officer	77	1986-03-30
Thomas Ohrt DFI	Director of Finance/CFO	70	2024-01-21

Director	Title	Age	Since
James Musick CHM	Chairman	77	1989-08-31
Christopher Furman BRD	Director/Board Member	55	2022-06-30
Caroline Mosessian CHM	Chairman	60	2022-04-30

Date	Insider	Type	Main position	Quantity	% Market Cap.
22-11-10	James Musick	Other	Founder	33,324,982	-
22-11-10	Nathan Haas	Other	Chief Financial Officer	4,421,299	-
22-11-10	Jack Zamora	Other	Chief Executive Officer	37,049,320	-

Vitro Diagnostics, Inc. Stock

Stocks

VODG

US9285013036

Pharmaceuticals

Latest news : Vitro Diagnostics, Inc.

Press Releases: Vitro Diagnostics, Inc.

Quotes and Performance

Managers and Directors: Vitro Diagnostics, Inc.

Latest insider transactions

Biopharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VITRO DIAGNOSTICS, INC.	+9.72%	+22.40%	-	-	18.29M
REGENERON PHARMACEUTICALS, INC.	+0.33%	-0.25%	+18.76%	-22.11%	61.85B
UCB	-1.27%	-8.04%	+60.62%	+190.51%	55.69B
SAMSUNG BIOLOGICS CO.,LTD.	+4.38%	+43.00%	+43.00%	+43.00%	41.88B
CSL LIMITED	+1.85%	+2.73%	-54.47%	-61.27%	36.15B
BIOGEN INC.	-1.05%	-1.69%	+55.35%	-33.92%	29.33B
MODERNA, INC.	+3.50%	+28.85%	+151.81%	-50.31%	24.52B
INCYTE CORPORATION	-0.78%	-8.91%	+43.87%	+55.34%	19.78B
INNOVENT BIOLOGICS, INC.	+1.74%	+4.39%	-3.12%	+107.49%	16.61B
SWEDISH ORPHAN BIOVITRUM AB	-0.05%	+0.41%	+56.32%	+94.95%	16.2B
Average	+1.84%	+3.21%	+41.35%	+35.96%	33.56B
Weighted average by Cap.	+0.90%	+2.24%	+37.89%	+36.48%